KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Tax Provisions (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Tax Provisions for 10 consecutive years, with $40.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 1.04% to $40.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $150.0 million, a 32.68% increase, with the full-year FY2025 number at $150.0 million, up 32.68% from a year prior.
  • Tax Provisions was $40.8 million for Q4 2025 at Halozyme Therapeutics, down from $43.7 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $154.2 million in Q3 2021 to a low of -$12.0 million in Q4 2021.
  • A 5-year average of $26.0 million and a median of $18.8 million in 2023 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 244661.9% in 2021; the steepest drop was 14170.59% in 2021.
  • Halozyme Therapeutics' Tax Provisions stood at -$12.0 million in 2021, then surged by 209.44% to $13.1 million in 2022, then rose by 20.63% to $15.8 million in 2023, then skyrocketed by 160.95% to $41.2 million in 2024, then decreased by 1.04% to $40.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Tax Provisions are $40.8 million (Q4 2025), $43.7 million (Q3 2025), and $39.8 million (Q2 2025).